Corvus Pharmaceuticals Stock Market Value
| CRVS Stock | USD 8.93 0.02 0.22% |
| Symbol | Corvus |
Corvus Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corvus Pharmaceuticals. If investors know Corvus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corvus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Return On Assets (0.24) | Return On Equity (0.45) |
The market value of Corvus Pharmaceuticals is measured differently than its book value, which is the value of Corvus that is recorded on the company's balance sheet. Investors also form their own opinion of Corvus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corvus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corvus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corvus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corvus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corvus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corvus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Corvus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Corvus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Corvus Pharmaceuticals.
| 10/26/2024 |
| 11/25/2024 |
If you would invest 0.00 in Corvus Pharmaceuticals on October 26, 2024 and sell it all today you would earn a total of 0.00 from holding Corvus Pharmaceuticals or generate 0.0% return on investment in Corvus Pharmaceuticals over 30 days. Corvus Pharmaceuticals is related to or competes with Mereo BioPharma, Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, Hookipa Pharma, X4 Pharmaceuticals, and Day One. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercializati... More
Corvus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Corvus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Corvus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.14 | |||
| Information Ratio | 0.236 | |||
| Maximum Drawdown | 23.11 | |||
| Value At Risk | (4.88) | |||
| Potential Upside | 9.38 |
Corvus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corvus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Corvus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Corvus Pharmaceuticals historical prices to predict the future Corvus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.2099 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | 0.5052 | |||
| Sortino Ratio | 0.2795 | |||
| Treynor Ratio | 0.7647 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Corvus Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Corvus Pharmaceuticals Backtested Returns
Corvus Pharmaceuticals is slightly risky given 3 months investment horizon. Corvus Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.28, which signifies that the company had a 0.28% return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.35% are justified by taking the suggested risk. Use Corvus Pharmaceuticals Risk Adjusted Performance of 0.2099, downside deviation of 4.14, and Mean Deviation of 3.66 to evaluate company specific risk that cannot be diversified away. Corvus Pharmaceuticals holds a performance score of 21 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corvus Pharmaceuticals will likely underperform. Use Corvus Pharmaceuticals value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Corvus Pharmaceuticals.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Corvus Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Corvus Pharmaceuticals time series from 26th of October 2024 to 10th of November 2024 and 10th of November 2024 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Corvus Pharmaceuticals price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Corvus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Corvus Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Corvus Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Corvus Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Corvus Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Corvus Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Corvus Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Corvus Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Corvus Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Corvus Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Corvus Pharmaceuticals Lagged Returns
When evaluating Corvus Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Corvus Pharmaceuticals stock have on its future price. Corvus Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Corvus Pharmaceuticals autocorrelation shows the relationship between Corvus Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Corvus Pharmaceuticals.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.